| P50 | author | Gilles Salles | Q17511518 |
| | Diane Damotte | Q37279300 |
| | Corinne Haioun | Q59200159 |
| | Christiane Copie Bergman | Q59621239 |
| | Philippe Gaulard | Q59676235 |
| | Anaïs Pujals | Q60473627 |
| | Francois Lemonnier | Q61054426 |
| | Elodie Bohers | Q90699425 |
| | Richard Delarue | Q117264788 |
| | Sydney Dubois | Q125187577 |
| | Karen Leroy | Q40687224 |
| | Alexandra Traverse-Glehen | Q41605418 |
| | Brigitte Sola | Q42638665 |
| | Sylvain Mareschal | Q43485518 |
| | Martin Dyer | Q53138021 |
| | Noel Jean Milpied | Q55743774 |
| | Thierry J Molina | Q56850574 |
| | Pierre-Julien Viailly | Q56939796 |
| | Thierry Fest | Q56997299 |
| | Martin Figeac | Q58914971 |
| P2093 | author name string | Philippe Bertrand | |
| | Peter Moeller | |
| | Fabrice Jardin | |
| | Hervé Tilly | |
| | Yosef Landesman | |
| | Vincent Camus | |
| | Laura Pelletier | |
| | Christian Bastard | |
| | Aspasia Stamatoullas | |
| | Jean-Philippe Jais | |
| | Catherine Maingonnat | |
| | Marie Cornic | |
| | Jean Michel Picquenot | |
| | Christer Sundstrom | |
| | Christian Argueta | |
| | Emilie Lemasle | |
| | Marlène Ochmann | |
| P2860 | cites work | Structural basis for leucine-rich nuclear export signal recognition by CRM1 | Q24604395 |
| | Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways | Q24652565 |
| | Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma | Q24672476 |
| | Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia | Q27674083 |
| | The GTP-binding domain of class II transactivator regulates its nuclear export | Q28202212 |
| | MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers | Q28306431 |
| | Genomic and molecular characterization of esophageal squamous cell carcinoma | Q28657686 |
| | A general framework for estimating the relative pathogenicity of human genetic variants | Q29615730 |
| | limma powers differential expression analyses for RNA-sequencing and microarray studies | Q29617988 |
| | B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity | Q29977777 |
| | Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation | Q33236181 |
| | Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. | Q33669371 |
| | Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 |
| | Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma | Q33934010 |
| | Jetset: selecting the optimal microarray probe set to represent a gene | Q34102011 |
| | FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma. | Q34221760 |
| | Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling | Q34328572 |
| | Nucleo-cytoplasmic transport as a therapeutic target of cancer | Q34452108 |
| | Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? | Q34802443 |
| | Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma | Q35095028 |
| | Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. | Q35143471 |
| | Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. | Q36322486 |
| | CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. | Q37445828 |
| | KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. | Q37693609 |
| | The molecular pathogenesis of primary mediastinal large B-cell lymphoma | Q37893841 |
| | Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? | Q38029564 |
| | Targeting the nuclear transport machinery by rational drug design | Q38053475 |
| | Understanding XPO1 target networks using systems biology and mathematical modeling | Q38093183 |
| | Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. | Q38930717 |
| | U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma | Q40384149 |
| | NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes | Q40427138 |
| | Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line | Q40486172 |
| | MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma | Q40814255 |
| | Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling | Q41620612 |
| | Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing | Q42175237 |
| | Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. | Q42986380 |
| | Rgb: a scriptable genome browser for R. | Q44093114 |
| | A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells | Q44714283 |
| | Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. | Q50492479 |
| | Evaluation of structural and evolutionary contributions to deleterious mutation prediction. | Q52032041 |
| | SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. | Q52644149 |
| | Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. | Q52887085 |
| | CRM1 as a new therapeutic target for non-Hodgkin lymphoma. | Q52997079 |
| | The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. | Q53931762 |
| | Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. | Q55055249 |
| | Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) | Q56978661 |
| | Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial | Q56985985 |
| P433 | issue | 9 | |
| P304 | page(s) | 923-930 | |
| P577 | publication date | 2016-06-16 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma | |
| P478 | volume | 91 | |